ANTIBODY BOUND TO NOVEL CORONAVIRUS (SARS-COV-2)

To provide a novel antibody that makes it possible to prevent and/or treat infection with COVID-19.SOLUTION: The present invention provides an antibody or an antibody fragment thereof, wherein the antibody has heavy chain CDR1 consisting of a specific amino acid sequence, heavy chain CDR2 consisting...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	SHIGA HAZUKI, MATSUKURA SUSUMU, WATANABE SHINYA, HOSHI HIROTAKA, SATO SHIGEKO, IMAI JUNICHI
Format:	Patent
Sprache:	eng ; jpn
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE FOODS OR FOODSTUFFS FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT THEIR TREATMENT, NOT COVERED BY OTHER CLASSES VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To provide a novel antibody that makes it possible to prevent and/or treat infection with COVID-19.SOLUTION: The present invention provides an antibody or an antibody fragment thereof, wherein the antibody has heavy chain CDR1 consisting of a specific amino acid sequence, heavy chain CDR2 consisting of a specific amino acid sequence, heavy chain CDR3 consisting of a specific amino acid sequence, light chain CDR1 consisting of a specific amino acid sequence, light chain CDR2 consisting of a specific amino acid sequence, and light chain CDR3 consisting of a specific amino acid sequence, and the antibody is bound to the S2 subunit of SARS-CoV-2.SELECTED DRAWING: None 【課題】COVID-19に対する感染予防および／または治療を可能とする新規抗体の提供を課題とする。【解決手段】特定のアミノ酸配列からなる重鎖CDR１、特定のアミノ酸配列からなる重鎖CDR2、特定のアミノ酸配列からなる重鎖CDR3、特定のアミノ酸配列からなる軽鎖CDR1、特定のアミノ酸配列からなる軽鎖CDR2、および、特定のアミノ酸配列からなる軽鎖CDR3を有する抗体であって、SARS-CoV-2のS2サブユニットに結合する、抗体またはその抗体フラグメント。【選択図】なし